NGM Bio to Participate in Upcoming Investor Conferences
NGM Biopharmaceuticals, Inc. (NGM) has announced that CEO David J. Woodhouse, Ph.D., will present a company overview and business update at two upcoming investor conferences. The presentations will take place at the Jefferies Healthcare Conference on June 9, 2022, at 8:30 am ET, and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 12:20 pm ET. Live webcasts and replays will be available on NGM's website following the events. NGM focuses on developing innovative therapeutics across several areas, including cancer and metabolic diseases.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences.
Jefferies Healthcare Conference
Thursday, June 9, 2022, 8:30 am ET
Goldman Sachs 43rd Annual Global Healthcare Conference
Tuesday, June 14, 2022, 12:20 pm ET
Live webcasts of the presentations will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of each presentation will be archived on NGM Bio’s site for at least 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has seven programs in active development, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases. Visit us at www.ngmbio.com for more information.
| Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: media@ngmbio.com |
FAQ
When will NGM Biopharmaceuticals present at the Jefferies Healthcare Conference?
What is the date and time for NGM's presentation at the Goldman Sachs Conference?
Where can I watch the NGM Biopharmaceuticals investor presentations?
What therapeutic areas is NGM Biopharmaceuticals focusing on?
How many programs does NGM Biopharmaceuticals have in active development?
